Stoke Therapeutics Inc

STOK is entrenched in a Stage 4 decline following a high-volume support failure beneath the 29.65 zone, confirming a new downtrend with lower highs and lower lows under declining EMAs. Medium-term bias remains bearish as price trades below the 9/20/50 EMA cluster, and short-term bounces into the 30.00 6.00 6031.00 zone have been rejected, with momentum still negative and no mean-reversion eligibility. The optimal engagement is to sell now into structural resistance on any rally.

• ↑74% convulsive seizure reduction in interim Zoriva-Nursen trials
• ↑$411M cash runway into 2028 ensures Phase III funding
• ↓Net loss of $38.3M in Q3 elevates cash burn risk